Financial Counselors Inc. Has $549,000 Stake in Sanofi (NASDAQ:SNY)

Financial Counselors Inc. reduced its position in shares of Sanofi (NASDAQ:SNY) by 12.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,525 shares of the company’s stock after selling 1,310 shares during the quarter. Financial Counselors Inc.’s holdings in Sanofi were worth $549,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. Barrow Hanley Mewhinney & Strauss LLC grew its position in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC grew its holdings in shares of Sanofi by 1,153.1% during the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on SNY shares. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $48.49 on Friday. The stock has a market capitalization of $123.06 billion, a P/E ratio of 24.74, a P/E/G ratio of 1.23 and a beta of 0.61. The business has a 50-day moving average of $52.80 and a two-hundred day moving average of $52.13. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the business earned $2.55 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post 4.29 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.